CVMCX
Price
$16.88
Change
-$0.13 (-0.76%)
Updated
Dec 17 closing price
FNWFX
Price
$82.52
Change
-$0.32 (-0.39%)
Updated
Dec 17 closing price
Ad is loading...

CVMCX vs FNWFX

Header iconCVMCX vs FNWFX Comparison
Open Charts CVMCX vs FNWFXBanner chart's image
Calvert Emerging Markets Equity C
Price$16.88
Change-$0.13 (-0.76%)
VolumeN/A
CapitalizationN/A
American Funds New World F3
Price$82.52
Change-$0.32 (-0.39%)
VolumeN/A
CapitalizationN/A
CVMCX vs FNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CVMCX vs. FNWFX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVMCX is a Buy and FNWFX is a Buy.

FUNDAMENTALS
Fundamentals
FNWFX has more cash in the bank: 64.3B vs. CVMCX (1.28B). FNWFX pays higher dividends than CVMCX: FNWFX (1.56) vs CVMCX (0.00). CVMCX was incepted earlier than FNWFX: CVMCX (12 years) vs FNWFX (8 years). CVMCX is a more actively managed with annual turnover of: 59.00 vs. FNWFX (32.00). CVMCX has a lower initial minimum investment than FNWFX: CVMCX (1000) vs FNWFX (1000000). CVMCX (12.06) and FNWFX (12.00) have marching annual gain over last year. FNWFX return over 5 years is better than : 16.03 vs. CVMCX (-0.76).
CVMCXFNWFXCVMCX / FNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years8 years-
Gain YTD9.10810.02791%
Front LoadN/AN/A-
Min. Initial Investment100010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.28B64.3B2%
Annual Yield % from dividends0.001.56-
Returns for 1 year12.0612.00100%
Returns for 3 years-12.360.71-1,742%
Returns for 5 years-0.7616.03-5%
Returns for 10 years37.99N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BRC75.93-0.76
-0.99%
Brady Corp
GEN29.38-0.35
-1.18%
Gen Digital
SACH1.24-0.03
-2.36%
Sachem Capital Corp
NN17.55-0.45
-2.50%
NextNav
CANF1.42-0.09
-5.96%
Can-Fite BioPharma Ltd